# US 2025/0084393 A1 · Nucleic acid molecules encoding dna modifying enzymes and active fragments and variants thereof and compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084393 A1
- Document ID: US20250084393A1
- Status: Published application
- Kind: A1
- Application number: 18/955,480
- Filed: 2024-11-21
- Published: 2025-03-13
- Earliest claimed: 2020-09-11
- Assignees: Life Edit Therapeutics, Inc.
- Applicants: Life Edit Therapeutics, Inc.
- Inventors: Tyson D. Bowen; Alexandra Briner Crawley; Tedd D. Elich
- Web page: https://patentgrep.com/patent/US20250084393A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Y 305/01004: Amidase (3.5.1.4)
- C12Y 305/04002: Adenine deaminase (3.5.4.2)
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C07K 2319/85: containing an RNA binding domain
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

## Claims

### Claim 1

A method for modifying a target DNA molecule, said method comprising delivering a system comprising:
a) a fusion protein comprising a Type II CRISPR-Cas protein nickase and a deaminase, wherein said deaminase comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 407 and has adenine deaminase activity, and wherein said nickase
(i) is a Cas9 nickase; or
(ii) comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398; and
b) one or more guide RNAs (gRNAs) capable of hybridizing to said target DNA molecule or one or more nucleotide sequences encoding the one or more gRNAs;
to said target DNA molecule or a cell comprising the target DNA molecule, wherein the one or more gRNAs are capable of forming a complex with the fusion protein in order to direct said fusion protein to bind to and modify said target DNA molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein said modified target DNA molecule comprises an A>N mutation of at least one nucleotide within the target DNA molecule, wherein N is C, G, or T.

### Claim 3 (depends on 2)

The method of claim 2, wherein said modified target DNA molecule comprises an A>G mutation of at least one nucleotide within the target DNA molecule.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nickase has the amino acid sequence of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398.

### Claim 5 (depends on 1)

The method of claim 1, wherein said deaminase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 407 and has adenine deaminase activity.

### Claim 6 (depends on 1)

The method of claim 1, wherein said deaminase comprises the amino acid sequence of SEQ ID NO: 407.

### Claim 7 (depends on 1)

The method of claim 1, wherein the fusion protein further comprises a protein tag or a cell penetrating domain.

### Claim 8 (depends on 1)

The method of claim 1, wherein the fusion protein further comprises at least one nuclear localization signal (NLS).

### Claim 9 (depends on 1)

The method of claim 1, wherein said fusion protein comprises the amino acid sequence of SEQ ID NO: 496.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least one of said one or more nucleotide sequences encoding the one or more gRNAs is operably linked to a promoter.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cell comprising the target DNA molecule is a eukaryotic cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the eukaryotic cell is a mammalian cell.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method is performed in vitro, ex vivo, or in vivo.

### Claim 14 (depends on 1)

The method of claim 1, wherein said method comprises viral vector delivery.

### Claim 15 (depends on 14)

The method of claim 14, wherein said viral vector delivery comprises an adenovirus-associated viral (AAV) vector.

### Claim 16 (depends on 1)

The method of claim 1, wherein said method comprises lipid particle delivery.

### Claim 17 (depends on 16)

The method of claim 16, wherein said lipid particle comprises a ribonucleoprotein (RNP) complex comprising said system.

### Claim 18 (depends on 1)

The method of claim 1, wherein said one or more gRNAs comprises at least two gRNAs.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least two gRNAs are capable of hybridizing to two different target DNA molecules.

### Claim 20

A fusion protein comprising a Type II CRISPR-Cas protein nickase and a deaminase, wherein said deaminase comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 407 and has adenine deaminase activity, and wherein said nickase
(a) is a Cas9 nickase; or
(b) comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398.
